{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-22-000035","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2022-04-25T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.030854+00:00","generated_at":"2026-06-26T05:05:20.904635+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Gossamer Bio Phase 2 SHIFT-UC trial of GB004 misses primary endpoint; study terminated","bullets":["Phase 2 trial of GB004 in mild-to-moderate active UC failed primary endpoint at week 12 (15.4% QD, 22.5% BID vs. placebo 17.9%).","No meaningful differences on secondary endpoints; Gossamer terminates treat-through and open-label extension portions.","Preliminary cash, cash equivalents, and marketable securities ~$272M as of March 31, 2022 (unaudited).","Target enrollment of 80 patients reached in Phase 2 TORREY trial of seralutinib in PAH; topline results expected Q4 2022.","Anticipates initiation of Phase 1b/2 STAR CNS trial of GB5121 in primary CNS lymphoma in late Q2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-22-000035","json":"https://secwatch.observer/filing/0001728117-22-000035.json","markdown":"https://secwatch.observer/filing/0001728117-22-000035.md","text":"https://secwatch.observer/filing/0001728117-22-000035.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811722000035/0001728117-22-000035-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811722000035/goss-20210425x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T05:05:20.904635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}